ARA-290: Research Roundup

ARA-290 (also called cibinetide in development literature) is an 11-amino-acid peptide engineered from the helix-B surface of erythropoietin — designed to activate tissue-protective signaling without stimulating erythropoiesis. Brines and Cerami's work established that erythropoietin mediates cytoprotection through a heteroreceptor complex involving the erythropoietin receptor and CD131 (common β-subunit), termed the innate repair receptor in subsequent literature. Full EPO raises hematocrit and carries vascular risk profiles unsuitable for chronic tissue-protection research; ARA-290 was developed to engage repair pathways selectively. Phase 2 data in type 2 diabetes with neuropathic symptoms reported improved pain scores, glycemic markers, and corneal nerve fiber density in defined subgroups — human evidence beyond the preclinical-only profile of many catalog peptides like BPC-157, though ARA-290 remains investigational without FDA approval. This roundup summarizes ARA-290 pharmacology and material expectations. It is research information only; it contains no administration guidance.

What the literature describes

Brines and colleagues described nonerythropoietic peptides derived from EPO tertiary structure, including sequences that bind the innate repair receptor and reduce injury in neuropathic and ischemic preclinical models. ARA-290 emerged as a lead compound for clinical translation in sarcoidosis-associated neuropathy, diabetic neuropathy, and metabolic endpoints.

Dahan and coworkers reported a phase 2 study in type 2 diabetes: daily subcutaneous ARA 290 4 mg for 28 days improved HbA1c and lipid profiles over 56 days of observation and significantly improved neuropathic symptom scores versus placebo, with corneal confocal microscopy showing increased nerve fiber density in subjects with baseline deficiency. No major safety signals were identified in that trial's published account — though phase 2 data require confirmation in larger programs.

Preclinical literature extends to cisplatin nephrotoxicity, cerebral ischemia, and inflammatory injury models, generally reporting reduced apoptosis and cytokine elevation when β-common receptor signaling is intact.

Brines and Cerami's 2008 PNAS work on nonerythropoietic peptides derived from EPO structure provides the discovery-layer context for ARA-290 — selective engagement of tissue-protective pathways without the erythropoietic activity that limits chronic EPO use in anemia management.

Mechanism and research context

ARA-290 signaling is framed as selective innate repair receptor activation — distinct from EPO-driven erythropoiesis and from connective-tissue peptides BPC-157 or TB-500 actin-binding biology. B7-33 targets relaxin receptors in fibrosis; ARA-290 occupies EPO-adjacent cytoprotection literature.

Metabolic peptides semaglutide improve glycemic control through incretin receptors — a separate mechanism from ARA-290's published neuropathy and tissue-protection endpoints, though both appear in diabetes-adjacent research discussions.

Corneal confocal microscopy endpoints in the phase 2 diabetes trial link ARA-290 to small-fiber neuropathy research — a specialized outcome measure that does not generalize to generic "nerve repair" claims without matching assessment methodology.

Preclinical findings

Rodent neuropathy, kidney injury, stroke, and inflammatory models report tissue protection when ARA-290 or related peptides are administered in protocol-defined windows. β-common receptor knockdown attenuates effects in several papers, supporting receptor specificity hypotheses. Translation to chronic human neuropathy remains under investigation.

Clinical and formal studies

Phase 2 trials in sarcoidosis neuropathy and type 2 diabetes constitute the primary indexed human record. ARA-290 is not FDA-approved; development status has shifted with sponsor commercial decisions — researchers should verify current trial registration rather than assuming active phase 3 programs.

Brines and Cerami's broader reviews position innate repair receptor biology as a general tissue-stress response module — relevant to neuropathy, kidney ischemia, and metabolic inflammation models. ARA-290 is one engineered ligand in that framework; it should not be equated with erythropoietin dosing in renal anemia, where hematocrit elevation is the therapeutic goal.

Sarcoidosis-associated neuropathy trials explored ARA-290 in orphan-disease contexts with small cohorts. Published accounts emphasize symptom and quality-of-life endpoints rather than large hard-outcome trials — appropriate for phase 2 but limiting for general catalog claims.

Material quality evaluation

ARA-290 is a short defined 11-mer; expected mass is analytically straightforward when correctly synthesized. Mislabeling as EPO fragments, BPC-157, or unrelated cytoprotective peptides occurs in crowded catalog markets.

Require MS identity, HPLC chromatogram, lot traceability, and independent testing per COA literacy and HPLC vs. MS. Peptide identity testing and vetting apply.

Related reading

Tissue protection comparators: BPC-157, TB-500, thymosin beta-4, B7-33. Bone anabolic approved peptides: teriparatide, abaloparatide. Metabolic context: semaglutide. Library entry: ARA-290.

Limitations recap

ARA-290 remains investigational. Phase 2 neuropathy and metabolic findings require larger confirmatory trials. Innate repair receptor biology is complex; not all preclinical models replicate in humans. Catalog material is not clinical trial drug product. This page excludes dosing and personal-use instructions.

Leist and colleagues' carbamylated EPO work established that tissue protection could be separated from erythropoiesis — the conceptual foundation ARA-290 builds on. Catalog peptides labeled "EPO fragment" without sequence match to ARA-290's defined 11-mer should be rejected at procurement.

Recent mouse stroke literature reports ARA290 neuroprotection dependent on β-common receptor signaling — extending preclinical claims beyond diabetic neuropathy into ischemia models without phase 3 human confirmation.